Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hyperhidrosis Treatment Market

Hyperhidrosis Treatment Market Share

Report ID: GMI9862
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Hyperhidrosis Treatment Market Share

The market is characterized by a competitive landscape with several key players vying for market share. Companies operating in this market are focused on developing innovative treatment modalities, expanding their product portfolios, and strengthening their presence in key regions to gain a competitive edge.

Hyperhidrosis Treatment Market Companies

Prominent players operating in the hyperhidrosis treatment industry include:

AbbVie Inc.
Avanor Healthcare Ltd.
Brickell Biotech Inc.
Dermadry Laboratories Inc.
Dermavant Sciences Inc.
Hugel, Inc.
Eirion Therapeutics, Inc
Eli Lilly and Company
Intas Pharmaceuticals Ltd
Kaken Pharmaceutical Co., Ltd.
Maruho Co., Ltd.
miraDry, Inc.
SweatBlock

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global hyperhidrosis treatment industry was valued at USD 671.6 million in 2023 and is anticipated to register 5.3% CAGR between 2024 and 2032 due to the increasing prevalence of hyperhidrosis and growing awareness and diagnosis rates.

The axillary segment in the market held 44.8% revenue share in 2023 due to high prevalence of axillary hyperhidrosis and wide range of effective treatment options that are readily available and widely accepted by both patients and healthcare providers.

North America hyperhidrosis treatment market size is expected to record 5% CAGR between 2024 and 2032 due to the presence of advanced healthcare infrastructure, technological advancements and ongoing research initiatives.

AbbVie Inc., Avanor Healthcare Ltd., Brickell Biotech Inc., Dermadry Laboratories Inc., Dermavant Sciences Inc., Hugel, Inc., Eirion Therapeutics, Inc, Eli Lilly and Company, Intas Pharmaceuticals Ltd and Kaken Pharmaceutical Co., Ltd., among others.